Drug Type Small molecule drug |
Synonyms |
Mechanism CXCR4 antagonists(C-X-C motif chemokine receptor 4 antagonists), β2-adrenergic receptor antagonists(Beta-2 adrenergic receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H22ClNO2 |
InChIKeyZMRUPTIKESYGQW-UHFFFAOYSA-N |
CAS Registry318-98-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Phase 2 | US | 13 Feb 2023 | |
Acute Myeloid Leukemia | Preclinical | KR | - | |
Solid tumor | Preclinical | KR | - |